http://www.bmrat.org/index.php/BMRAT/issue/feed Biomedical Research and Therapy 2019-09-16T11:59:48+00:00 Lili Hami managingeditor@bmrat.org Open Journal Systems http://www.bmrat.org/index.php/BMRAT/article/view/562 Outcome analysis of acute myeloid leukemia patients treated with high dose daunorubicin 2019-09-16T11:59:48+00:00 http://www.bmrat.org/public/journals/2/article_562_cover_en_US.jpg Roya Dolatkhah phamvanphuc2308@gmail.com Effat Irani Jam phamvanphuc2308@gmail.com Alireza Nikanfar phamvanphuc2308@gmail.com Ali Esfahani phamvanphuc2308@gmail.com Sayed Hadi Chavooshi phamvanphuc2308@gmail.com Babak Nejati phamvanphuc2308@gmail.com Zohreh Sanaat zohrehsanaat@yahoo.com <p><strong>Abstract</strong>: Acute Myeloid Leukemia (AML) is a malignant hematopoietic disease caused by the presence of a malignant clone in the bone marrow. The classic AML treatment includes a combination of an Anthracycline and Cytarabine. This study aimed to evaluate the effect of high doses of Daunorubicin on patients' outcome.</p> <p><strong>Methods</strong>: During the study period, 16 AML patients received induction therapy with Cytarabine (100 mg/m2/d) for 7 days and Daunorubicin (90 mg/m2/d) for 3 days. Outcome analysis was performed to evaluate the overall survival (OS) and disease-free survival (DFS) during 2 years of study.</p> <p><strong>Results</strong>: The mean age of patients was 38+/-12.38 years, with the age range between 16 and 54 years old. Seven patients (43.8%) were females, and 9 cases (56.3%) were males. OS was 81.3%, with a mean of 396.88 days. (95% CI: 306.99-486.77). DFS was 83.3%, with a mean of 383.57 days (95% CI: 299.88-467.26). The log-rank test showed a significant difference in DFS of AML sub-types, as M1 subtypes had lower DFS (P log-rank= 0.013). Although M1 subtypes had a lower OS, there was no significant difference in OS between subgroups (P log-rank= 0.067).</p> <p><strong>Conclusion</strong>: Although disease-free survival was improved by increasing the dose of daunorubicin, there was no difference in the overall survival between the AML subgroups and sexes.</p> <p>&nbsp;</p> 2019-09-10T00:00:00+00:00 ##submission.copyrightStatement##